Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After two failed studies, The Medicines Co.’s rapid-acting I.V. antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.

You may also be interested in...



Filings In The Second Half Could Be Transformative For The Medicines Co.

The Medicines Co.’s transition away from near-total reliance on Angiomax seems ever closer to reality, given its full pipeline and intensive business development activities. The new products stretch beyond the hospital catheterization lab, as the company builds franchises in hospital anti-infectives, pain management, and hemostatis.

The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III

TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.

Is TMS' Cangrelor A CHAMPION After All? "Noise On The Line" Confounded Endpoint Data, CEO Says

Speeding heart attack patients into the PCI lab may have blurred the timeline on their MIs and botched endpoint data, says Meanwell.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS005374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel